POLYMORPHISM OF INTERLEUKIN-10 (-819) GENE IS NOT ASSOCIATED WITH LIVER DAMAGE AMONG CHRONIC HEPATITIS B PATIENTS by Ramadhani, Nur'aina ID & Arfianti, Arfianti
Polymorphism of Interleukin-10…  Ramadhani NID, Arfianti 
 
 183 
POLYMORPHISM OF INTERLEUKIN-10 (-819) GENE IS NOT ASSOCIATED 
WITH LIVER DAMAGE AMONG CHRONIC HEPATITIS B PATIENTS  
Nur'aina ID Ramadhani1), Arfianti2)*)  
 
ABSTRACT 
Introduction: Chronic hepatitis B (CHB) is characterized by chronic liver inflammation and 
hepatocellular damage caused by hepatitis B virus (HBV), leading to fatal liver diseases such 
as cirrhosis and hepatocellular carcinoma (HCC). Liver damage causes elevated levels of 
serum alanine aminotransferase (ALT). Previous studies have shown that IL-10 gene 
polymorphism (-819 C/T) is linked to several diseases, including inflammatory, autoimmune 
diseases, and cancer.  
Purpose: To investigate the relationship between IL-10 gene polymorphisms (-819 C/T) and 
liver damages in chronic hepatitis B patients at Arifin Achmad Regional Hospital, Riau 
Province. 
Method: This study was an analytical study with a cross-sectional approach. Liver damages 
were examined by measuring ALT levels, and IL-10 gene polymorphisms were analyzed 
using Amplification-Refractory Mutation System Polymerase Chain Reaction (ARMS-PCR).  
Results: There were 74 subjects included in this study, aged 45.47±13.42 years old, 
consisting of 43 males (58.1%) and 31 females (41.9%). Of 74 subjects, 35 CHB patients 
were presented without complication, 26 CHB patients were complicated with cirrhosis, and 
13 CHB patients were complicated with hepatoma. The genotype of the IL-10 (-819) gene 
polymorphism in this study was found as follows: CT genotype in 34 subjects (45.9%), TT 
genotype in 30 subjects (40.5%), and CC genotype in 10 subjects (13.5%). There was no 
significant relationship between IL-10 gene polymorphisms (- 819) and liver damage in 
chronic hepatitis B patients (p> 0.05). 
Conclusion: IL-10 gene polymorphism (-819) may not contribute to liver damages among 
CHB patients.  
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Hepatitis B virus (HBV) is a 
hepatotropic virus that causes 
inflammation and damage to the liver. 
Patients with chronic hepatitis B 
(CHB) with persistent inflammation 
and liver damage are at increased risk 
of developing fatal liver diseases such 
as cirrhosis and hepatocellular 
carcinoma (HCC). HCC is the most 
common liver cancer and is one of the 
second-highest death rates in the world 
(Hepatitis B, 2017). 
Chronic hepatitis B is a global 
health problem. The World Health 
Organization (WHO) estimates that 
approximately 3.5% of the world's 
population suffers from chronic 
hepatitis B and causes 887,000 deaths 
each year (Hepatitis B, 2017). The Asia 
Pacific region is the most significant 
contributor to hepatitis B and liver 
cancer burden worldwide, with 74% of 
global liver cancer deaths occurring in 
Asia (World Health Organization, 
2019). Previous studies reported that 
40-50% of hepatic cirrhosis patients in 
Indonesia were underlined with chronic 
hepatitis B infection (World Health 
Organization, 2019). In addition, the 
Global Cancer Observatory 
(GLOBOCAN) stated that in 2018 
there were 18,468 new cases of liver 
cancer and 18,148 deaths due to liver 
cancer in Indonesia (World Health 
Organization, 2019). 
Based on the 2013 Basic Health 
Research (RISKESDAS) quoted from 
Muljono (Muljono, 2017), Indonesia is 
classified as moderate endemicity for 
hepatitis B infection with a positive 
HBsAg prevalence of 7.1 (Muljono, 
2017). The prevalence of positive 
HBsAg in Indonesia varies 
geographically, ranging from 4-20.3%, 
where the prevalence of hepatitis B 
patients outside Java Island is more 
significant than in Java island 
(Mulyanto et al., 2010).  
Hepatitis B virus is a DNA virus of 42 
nm in diameter with a double-layered 
protein coat belonging to the 
hepadnaviridae family. The outer 
sheath contains HBsAg, which can be 
detected in the circulation, while the 
inside consists of a nucleocapsid 
composed of HBcAg (Soemoharjo, 
2008). HBV is a non-cytopathic virus, 
which means that the virus does not 
directly cause the liver damage in 
chronic hepatitis B patients but is due 
to the body's immune response to HBV 
infected hepatocytes (Soemoharjo, 
2008).  
The liver inflammation within 
chronic hepatitis B patients can cause 
liver damage as indicated by abnormal 
levels of liver enzymes, namely 




(AST/SGOT) and alanine 
aminotransferase (ALT/SGPT). 
Hepatocellular injury releases ALT 
from the damaged liver cells leading to 
an increase in serum ALT levels. In 
acute hepatocellular injury, usually, 
AST levels will increase faster, even 
higher than ALT levels, because AST 
activity is higher in hepatocytes. 
However, in the next 24 to 48 hours, 
ALT levels will be higher than AST. 
Chronic hepatitis B infection is the 
most common cause of elevated ALT 
levels (Kim et al., 2008). 
Interleukin-10 (IL-10) is an anti-
inflammatory cytokine that plays an 
essential role in regulating 
inflammatory responses to prevent 
excessive liver cell damage and 
maintain organ function. 
Polymorphisms within the promoter of 
the IL-10 gene have been widely 
reported, and although they do not 
cause changes in protein structure, they 
are known to affect the expression of 
IL-10 proteins. These include single 
nucleotide polymorphism (SNP) at 
positions -592  (C/A), -819 C/T, and -
1082 A/G) (Gao et al., 2016). A 
previous study showed that the IL-10 
gene polymorphism (-819 C/T) was 
frequently found in chronic hepatitis B 
patients with liver cirrhosis (Baghi et 
al., 2015). Another study has 
demonstrated that IL-10 gene 
polymorphisms were associated with 
the risk of periodontitis (Distribution 
and Periodontitis, 2016), some 
enterovirus infections (Zhao et al., 
2017), and humane immune deficiency 
(HIV) (Sobti et al., 2010). Given the 
vital role of the immune response on 
the pathogenesis of chronic hepatitis B, 
this study aimed to analyze the 
association between IL-10 gene 
polymorphisms (-819 C/T) and liver 
damage in chronic hepatitis B patients. 
 
METHOD 
 This study was an analytical study 
with a cross-sectional approach to 
seeking the association between IL-10 
gene polymorphisms (-819 C/T) and 
liver damage in chronic hepatitis B 
patients. Study subjects were recruited 
from March to October 2019 at the 
Internal Medicine Outpatient Clinic at 
the Arifin Achmad Regional Hospital, 
Riau Province. The inclusion criteria 
were chronic hepatitis B patients aged 
18 years old and agreed to participate 
in this study. Serum ALT levels were 
examined at one of the clinical 
laboratories in Pekanbaru. IL-10 gene 
polymorphisms (-819 C/T) were 
characterized at LONTAR Integrated 
Biomedical Laboratory, Faculty of 
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Medicine, Riau University, between 
December 2020 and March 2021. 
 Genomic DNA was isolated from 
the blood fraction of EDTA-treated 
blood that was stored at -80oC until 
further procedures. DNA isolation was 
carried out using the Wizard Genomic 
DNA Purification kit (Promega, 
Madison, WI, USA). Genomic DNA 
was stored at -20oC until the next 
process. 
IL-10 gene (-819) polymorphism was 
carried out using the Amplification 
Refractory Mutation System - 
Polymerase Chain Reaction (ARMS-
PCR) method (Gao et al., 2016), which 
uses specific primers to detect 
polymorphism alleles. The primary 
sequences were adopted from Perrey et 
al. (Perrey et al., 1999). PCR 
conditions consisted of initial 
denaturation at 95oC for 1 minute, 
followed by ten cycles of denaturation 
at 94oC for 15 seconds; annealing at 
59oC for 50 seconds, extension at 72oC 
for 50 seconds, and final extension at 
72oC for 7 minutes. PCR products were 
run on 2% agarose stained with 
GelâRed (Biotium, USA). 
Electrophoresis results were visualized 
using GelDoc (Bio-Rad, USA) (Al-
Mohaya et al., 2015). 
 Univariate analysis was carried out 
to describe categorical data presented 
in proportions, while numerical data 
(age) was presented as mean±SD. The 
relationship between IL-10 gene 
polymorphism (-819) and liver damage 
in chronic hepatitis B patients was 
analyzed using the Pearson Chi-square 
test, and p-value <0.05 was deemed 
significant. 
 
RESULTS AND DISCUSSION 
This study analyzed 74 CHB patients at 
Arifin Achmad Regional Hospital, 
Riau Province, recruited from March to 
October 2019. The characteristic of 
study subjects can be seen in Table 1. 
 




n = 35 
CHB with 
Cirrhosis 
n = 26 
CHB with 
Hepatoma 
n = 13 
Age (Mean±SD, year) 38.17±13.17 51.19±9.22 53.69±11.29 
Gender    
Male (n /%) 14 / 40.0 20 / 76.9 9 / 69.2 




Polymorphism of Interleukin-10…  Ramadhani NID, Arfianti 
 
 187 
Based on Table 1, the mean age of 
CHB patients without complications in 
this study was 38.17±13.17 years. This 
result is in line with Bahgi et al. study 
conducted on the Iranian population, 
which found that the average age of 
chronic hepatitis B patients was 
38.5.±13.7 years (Baghi et al., 2015). 
Different results were reported by 
Talaat et al. in the Egyptian population, 
where the mean age of CHB patients 
was 42.66 ± 12.59 years (Talaat et al., 
2014) and Zhang et al. in the Indian 
population, with a mean age of 44.2 
years (Zhang et al., 2014). Differences 
in the mean age of CHB patients can be 
due to differences in the study 
population where the patients may 
have different disease progression and 
complications caused by chronic 
hepatitis B. This age difference can 
also be due to differences in the mode 
of hepatitis B transmission between 
regions. Hepatitis B infection is mainly 
transmitted from mother to baby during 
the perinatal period in Indonesia 
(vertical transmission). Primary HBV 
infection in neonates has a 95% risk for 
developing chronic hepatitis B. This 
may lead to a younger population of 
chronic hepatitis B patients. The mean 
age of chronic hepatitis B patients with 
cirrhosis in this study was 51.19±9.22 
years. This result is similar to a study 
by Arfianti et al. 2011 conducted in 
Pekanbaru, showing chronic hepatitis 
B patients aged 52.9 ± 11.3 years 
(Arfianti et al., 2011). Likewise, the 
mean age of chronic hepatitis B 
patients with hepatoma was 
53.69±11.29 years. Similar findings 
were also reported in a study in 
Pekanbaru with an average age of 48.2 
± 8.7 years (Arfianti et al., 2011).  
In this study, CHB patients with 
cirrhosis and hepatoma were mostly 
males, with the proportion of 76.9% 
and 70%, respectively. On the other 
hand, CHB patients without 
complication are predominantly 
females (60%), slightly higher than 
males (40%). The difference in the risk 
of complications of cirrhosis and 
hepatoma in CHB patients has been 
reported in various literature. This is in 
line with previous studies, which stated 
that in areas with vertical HBV 
transmission patterns such as 
Indonesia, males with chronic hepatitis 
B had a 50% greater risk of developing 
hepatoma progression than females 
(Ince et al., 1999). The mechanisms 
underlying the gender disparity in the 
risk of hepatoma are still not fully 
understood. Several studies suggest 
that testosterone increases the risk of 
developing hepatoma while 
progesterone is protective against the 
Online-ISSN 2565-1409 Journal of Widya Medika Junior Vol 3. No. 3 July 2021 
 
	 188 





Table 2 Profiles of Liver Damage in Chronic Hepatitis B patients 
ALT levels n % 
Normal 56 71.8 
Elevated 10 12.8 
No data  8 10.3 
 
The profiles of liver damage in  
CHB patients based on ALT levels are 
presented in Table 2. Most chronic 
hepatitis B patients demonstrated 
normal levels of serum ALT (71.8%), 
only 12.8%  of them having elevated 
ALT levels (>2x upper limit of 
normal). The remaining 10.3% of 
chronic hepatitis B patients did not 
have any ALT values in their medical 
records. The normal levels of serum 
ALT in this study indicate no liver 
damage associated with the risk of 
cirrhosis and hepatoma. Similar results 
were reported in the study of Trautwein 
et al. (Trautwein et al., 2015). Among 
120 chronic hepatitis B patients in the 
United Kingdom. This study found no 
significant relationship between 
chronic hepatitis B and liver damage 
(Samant, 2016). However, one study 
reported that chronic hepatitis B 
patients presented with ALT levels 20 
times higher than normal values (Thoni 
et al., 2017). This difference in ALT 
levels among chronic hepatitis B 
patients could be due to differences in 
the disease progression and 
complications in the study population. 
Chronic hepatitis B patients presenting 
with acute exacerbations tend to have 
higher ALT levels than those who do 
not (Liang, 2009).  
IL-10 gene electrophoresis showing 
genotype of IL-10 polymorphism (-819 
C/T) in chronic hepatitis B patients is 
presented in Figure 1. 




Figure 1. Gel Electrophoresis of IL-10 (819 C / T) gene fragment. M= DNA Marker. Row 
1,3,5= C allele. Row 2,4,6= T. 429 bp fragment =Internal Control. 233 bp fragment: IL-10 
gene. 
 
Genotype distribution of IL-10 gene 
polymorphisms (819 C/T) in CHB 
patients is presented in Table 3. Based 
on Table 3, 45.9% of CHB patients had 
CT genotype, 40.5% TT genotype, and 
13.5% CC genotype. Comparing the 
genotype distribution of the IL-10 gene 
polymorphism (-819 C/T) in this study 




Table 3 Genotype Distribution of IL-10 (-819) Gene Polymorphisms in Chronic Hepatitis 
B Patients 
Genotype IL-10 gene 
polymorphism (-819 C/T) 
n % 
CC  10 13.5 
CT  34 45.9 
TT  30 40.5 
 
Table 4 Comparison of Genotype Distribution of IL-10 Gene Polymorphisms (-819) 
between Different Population 
Research Population 
Genotype 
CC CT TT 





Baghi et al (Baghi et 




Talaat et al (Talaat et 
al., 2014) Egypt 60.0% 34.8% 5.2% 
Sofian et al (Sofian et Iran 46.9 6.2% 46.9
429	bp	
233	bp	
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al., 2013) % % 
Srivastava et al 






Liu et al (Liu Q et al., 




The relationship of IL-10 gene 
polymorphism (-819) with liver 
damage based on ALT levels in CHB 
patients can be seen in Table 5. 
 
Table 5 Relationship between IL-10 (-819) Gene Polymorphisms and Liver Damage in 
Chronic Hepatitis B Patients. 
Genotype of 
the IL-10 Gene   
Polymorphism (-819) 
ALT levels P 
value 
Elevated Normal  
n % n %  
CC 1 10.0 9 90.0 
0.929 CT 5 14.7 29 85.3 
TT 4 13.3 26 86.7 
 
Based on Table 5, most CHB 
patients had ALT levels within normal 
limits regardless of the IL-10 (-819) 
genotype. The statistical test showed 
that there was no significant 
relationship between the genotype 
distribution of the IL-10 gene 
polymorphism (-819C/T) with liver 
damage in chronic hepatitis B patients 
(p> 0.05). Research conducted by 
Saxena et al. reported that IL-10 (-819) 
gene polymorphism alleles have a 
linkage with the IL-10 (-592) gene 
polymorphism and the haplotype of 
these two polymorphisms has a 
significant relationship with the 
progression or risk of developing 
hepatoma in chronic hepatitis B 
patients (Saxena et al., 2014). Another 
study by Baghi et al. reported that the 
IL-10 (-819) and (-592) gene 
haplotypes were associated with the 
risk of cirrhosis in patients with 
chronic hepatitis B. Although this 
study also did not find any association 
between IL-10 gene polymorphisms (-
819) and the degree of liver damage in 
chronic hepatitis B patients (Baghi et 
al., 2015),(Talaat et al., 2014). In 
contrast, a study conducted by Ren et 
al. found a significant relationship 
between the IL-10 gene polymorphism 
(-819) with the degree of liver damage 
and its progression in the Asian 
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population (Ren, Zhang, and Hu, 
2015). 
This study did not find a significant 
relationship between the IL-10 gene 
polymorphism (-819) and liver 
damage, possibly because the sample 
size was relatively small, leading to 
limiting study power to find significant 
differences. Most of the previous 
studies included > 200 study subjects. 
In addition, several factors that are 
known to affect liver damage in 
chronic hepatitis B sufferers in this 
study were not controlled, such as 
genetic variants of HBV, host genetic 
susceptibility (HLA genes), comorbid 
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